|
US9217155B2
(en)
|
2008-05-28 |
2015-12-22 |
University Of Massachusetts |
Isolation of novel AAV'S and uses thereof
|
|
WO2010138263A2
(en)
|
2009-05-28 |
2010-12-02 |
University Of Massachusetts |
Novel aav 's and uses thereof
|
|
WO2011094198A1
(en)
*
|
2010-01-28 |
2011-08-04 |
The Children's Hospital Of Philadelphia Research Institute, Abramson Research Center |
A scalable manufacturing platform for viral vector purification and viral vectors so purified for use in gene therapy
|
|
DK2826860T3
(en)
|
2010-04-23 |
2018-12-03 |
Univ Massachusetts |
CNS targeting AAV vectors and methods for their use
|
|
CA2833905C
(en)
|
2010-04-23 |
2019-09-10 |
University Of Massachusetts |
Multicistronic expression constructs
|
|
EP3425044A1
(en)
*
|
2011-09-08 |
2019-01-09 |
uniQure IP B.V. |
Removal of contaminating viruses from aav preparations
|
|
EP3653212B1
(en)
|
2012-12-20 |
2023-04-26 |
Purdue Research Foundation |
Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
|
|
FR3002237B1
(fr)
*
|
2013-02-15 |
2017-12-15 |
Genethon |
Methodes pour la production de particules virales aav double brin
|
|
CA2930872C
(en)
|
2013-11-26 |
2022-05-31 |
University Of Florida Research Foundation, Incorporated |
Adeno-associated virus vectors for treatment of glycogen storage disease
|
|
GB201401707D0
(en)
|
2014-01-31 |
2014-03-19 |
Sec Dep For Health The |
Adeno-associated viral vectors
|
|
US10072251B2
(en)
|
2014-02-19 |
2018-09-11 |
University Of Massachusetts |
Recombinant AAVS having useful transcytosis properties
|
|
AU2015231294B2
(en)
|
2014-03-18 |
2020-10-29 |
University Of Massachusetts |
rAAV-based compositions and methods for treating amyotrophic lateral sclerosis
|
|
EP3628334B1
(en)
|
2014-03-21 |
2023-06-28 |
Genzyme Corporation |
Gene therapy for retinitis pigmentosa
|
|
US11555059B2
(en)
|
2014-04-25 |
2023-01-17 |
The Trustees Of The University Of Pennsylvania |
LDLR variants and their use in compositions for reducing cholesterol levels
|
|
WO2015164786A1
(en)
|
2014-04-25 |
2015-10-29 |
University Of Massachusetts |
Recombinant aav vectors useful for reducing immunity against transgene products
|
|
WO2015187825A2
(en)
|
2014-06-03 |
2015-12-10 |
University Of Massachusetts |
Compositions and methods for modulating dysferlin expression
|
|
WO2016054554A1
(en)
|
2014-10-03 |
2016-04-07 |
University Of Massachusetts |
Heterologous targeting peptide grafted aavs
|
|
EP3795580A1
(en)
|
2014-10-03 |
2021-03-24 |
University of Massachusetts |
High efficiency library-identified aav vectors
|
|
WO2016065001A1
(en)
|
2014-10-21 |
2016-04-28 |
University Of Massachusetts |
Recombinant aav variants and uses thereof
|
|
PT3224376T
(pt)
*
|
2014-11-28 |
2019-10-25 |
Uniqure Ip Bv |
Impurezas de dna numa composição compreendendo um vírus parvoviral.
|
|
US10415044B2
(en)
|
2014-12-23 |
2019-09-17 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Adeno-associated virus vectors encoding modified G6PC and uses thereof
|
|
SG11201704919SA
(en)
|
2015-01-13 |
2017-07-28 |
Alfa Wassermann Inc |
Methods of purifying adeno-associated virus (aav) and/or recombinant adeno-associated virus (raav)
|
|
EP3054006A1
(en)
|
2015-02-09 |
2016-08-10 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Recombinant adeno-associated virus particle purification with multiple-step anion exchange chromatography
|
|
EP3054007A1
(en)
|
2015-02-09 |
2016-08-10 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Recombinant adeno-associated virus particle purification comprising an immuno-affinity purification step
|
|
US10584321B2
(en)
|
2015-02-13 |
2020-03-10 |
University Of Massachusetts |
Compositions and methods for transient delivery of nucleases
|
|
US20180245073A1
(en)
*
|
2015-02-23 |
2018-08-30 |
Voyager Therapeutics, Inc. |
Regulatable expression using adeno-associated virus (aav)
|
|
EP3626274B1
(en)
|
2015-04-16 |
2025-01-22 |
Emory University |
Recombinant promoters and vectors for protein expression in liver and use thereof
|
|
CN107847612A
(zh)
|
2015-04-23 |
2018-03-27 |
华盛顿州立大学 |
递送Smad7基因作为治疗剂
|
|
CA3021949C
(en)
|
2015-04-24 |
2023-10-17 |
University Of Massachusetts |
Modified aav constructs and uses thereof
|
|
WO2017070525A1
(en)
|
2015-10-22 |
2017-04-27 |
University Of Massachusetts |
Methods and compositions for treating metabolic imbalance in neurodegenerative disease
|
|
US11426469B2
(en)
|
2015-10-22 |
2022-08-30 |
University Of Massachusetts |
Prostate-targeting adeno-associated virus serotype vectors
|
|
CN105420275A
(zh)
*
|
2015-11-27 |
2016-03-23 |
中国科学院苏州生物医学工程技术研究所 |
制备外源功能基因定点整合的人神经干细胞的方法
|
|
US11098286B2
(en)
|
2015-12-11 |
2021-08-24 |
The Trustees Of The University Of Pennsylvania |
Scalable purification method for AAV9
|
|
US11015173B2
(en)
|
2015-12-11 |
2021-05-25 |
The Trustees Of The University Of Pennsylvania |
Scalable purification method for AAV1
|
|
WO2017100676A1
(en)
|
2015-12-11 |
2017-06-15 |
The Trustees Of The University Of Pennsylvania |
Scalable purification method for aav8
|
|
CA3008142A1
(en)
*
|
2015-12-11 |
2017-06-15 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for treating familial hypercholesterolemia
|
|
EP3387118B1
(en)
|
2015-12-11 |
2022-04-06 |
The Trustees Of The University Of Pennsylvania |
Scalable purification method for aavrh10
|
|
WO2017106528A2
(en)
|
2015-12-18 |
2017-06-22 |
Sangamo Biosciences, Inc. |
Targeted disruption of the t cell receptor
|
|
MX2018007519A
(es)
|
2015-12-18 |
2019-09-04 |
Sangamo Therapeutics Inc |
Alteracion dirigida del receptor celular del complejo mayor de histocompatibilidad (mhc).
|
|
JP7012650B2
(ja)
|
2016-02-02 |
2022-01-28 |
サンガモ セラピューティクス， インコーポレイテッド |
Ｄｎａ結合ドメインと切断ドメインとを連結するための組成物
|
|
EP3411059A4
(en)
|
2016-02-02 |
2019-10-16 |
University Of Massachusetts |
METHOD FOR INCREASING THE EFFECTIVENESS OF THE SYSTEMIC DELIVERY OF AVV GENES TO THE CENTRAL NERVOUS SYSTEM
|
|
LT3411484T
(lt)
|
2016-02-05 |
2023-11-27 |
Emory University |
Viengrandžio arba sau pačiam komplementaraus adeno-asocijuoto viruso 9 injekcija į smegenų skystį
|
|
EP3413928B1
(en)
|
2016-02-12 |
2022-04-20 |
University of Massachusetts |
Anti-angiogenic mirna therapeutics for inhibiting corneal neovascularization
|
|
PH12018502104B1
(en)
|
2016-03-31 |
2024-03-27 |
Spark Therapeutics Inc |
Column-based fully scalable raav manufacturing process
|
|
US11207426B2
(en)
|
2016-04-05 |
2021-12-28 |
University Of Massachusetts |
Compositions and methods for selective inhibition of grainyhead-like protein expression
|
|
EP3439675A4
(en)
|
2016-04-08 |
2019-12-18 |
Purdue Research Foundation |
METHOD AND COMPOSITIONS FOR CAR-T CELL THERAPY
|
|
WO2017181105A1
(en)
|
2016-04-15 |
2017-10-19 |
University Of Massachusetts |
Methods and compositions for treating metabolic imbalance
|
|
WO2017218852A1
(en)
|
2016-06-15 |
2017-12-21 |
University Of Massachusetts |
Recombinant adeno-associated viruses for delivering gene editing molecules to embryonic cells
|
|
GB201612248D0
(en)
|
2016-07-14 |
2016-08-31 |
Puridify Ltd |
New process
|
|
RU2768045C2
(ru)
*
|
2016-07-21 |
2022-03-23 |
Спарк Терапьютикс, Инк. |
СПОСОБ ПОЛУЧЕНИЯ ЧАСТИЦ РЕКОМБИНАНТНОГО АДЕНОАССОЦИИРОВАННОГО ВИРУСНОГО ВЕКТОРА (rAAV)
|
|
WO2018022511A1
(en)
|
2016-07-25 |
2018-02-01 |
The Trustees Of The University Of Pennsylvania |
Compositions comprising a lecithin cholesterol acyltransferase variant and uses thereof
|
|
CN110225975A
(zh)
|
2016-08-23 |
2019-09-10 |
阿库斯股份有限公司 |
用于治疗人受试者中非年龄相关的听力损害的组合物和方法
|
|
SG11201901364VA
(en)
|
2016-08-24 |
2019-03-28 |
Sangamo Therapeutics Inc |
Engineered target specific nucleases
|
|
CR20190098A
(es)
|
2016-08-24 |
2019-04-30 |
Sangamo Therapeutics Inc |
Regulación de la expresión génica usando nucleasas modificadas
|
|
US10457940B2
(en)
|
2016-09-22 |
2019-10-29 |
University Of Massachusetts |
AAV treatment of Huntington's disease
|
|
US11578340B2
(en)
|
2016-10-13 |
2023-02-14 |
University Of Massachusetts |
AAV capsid designs
|
|
US11000561B2
(en)
*
|
2016-11-04 |
2021-05-11 |
Takeda Pharmaceutical Company Limited |
Adeno-associated virus purification methods
|
|
EP3321357A1
(en)
*
|
2016-11-09 |
2018-05-16 |
Deutsches Krebsforschungszentrum |
Scalable process for oncolytic rat parvovirus h-1 production and purification based on isoelectric point-based elimination of empty particles
|
|
WO2018140946A1
(en)
|
2017-01-30 |
2018-08-02 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Recombinant virus vectors for the treatment of glycogen storage disease
|
|
US11649288B2
(en)
|
2017-02-07 |
2023-05-16 |
Seattle Children's Hospital |
Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents
|
|
KR20190118163A
(ko)
|
2017-02-20 |
2019-10-17 |
더 트러스티스 오브 더 유니버시티 오브 펜실바니아 |
가족성 고콜레스테롤혈증을 치료하기 위한 유전자 요법
|
|
ES3010559T3
(en)
|
2017-02-28 |
2025-04-03 |
Endocyte Inc |
Compositions and methods for car t cell therapy
|
|
EP3622073A4
(en)
|
2017-05-09 |
2021-01-06 |
University of Massachusetts |
METHOD FOR TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
|
|
US11633504B2
(en)
|
2017-05-09 |
2023-04-25 |
Emory University |
Nucleic acids encoding clotting factor variants and their use
|
|
AU2018281306B2
(en)
|
2017-06-07 |
2025-04-17 |
Spark Therapeutics, Inc. |
Enhancing agents for improved cell transfection and/or rAAV vector production
|
|
MX2020000216A
(es)
*
|
2017-06-30 |
2020-09-03 |
Spark Therapeutics Inc |
Metodos de purificacion por columna de vectores aav.
|
|
WO2019032675A1
(en)
|
2017-08-08 |
2019-02-14 |
Sangamo Therapeutics, Inc. |
CELL TARGETING MEDIATED BY A CHIMERIC ANTIGEN RECEPTOR
|
|
JP7397488B2
(ja)
|
2017-09-22 |
2023-12-13 |
ユニバーシティ オブ マサチューセッツ |
Ｓｏｄ１二重発現ベクターおよびその使用
|
|
CN111433367A
(zh)
|
2017-10-20 |
2020-07-17 |
全国儿童医院研究所 |
Nt-3基因疗法的方法和材料
|
|
IL274430B2
(en)
*
|
2017-11-08 |
2025-01-01 |
Novartis Gene Therapies Inc |
Means and method for preparing viral vectors and their uses
|
|
AU2019209428B2
(en)
|
2018-01-22 |
2025-06-26 |
Endocyte, Inc. |
Methods of use for CAR T cells
|
|
US10610606B2
(en)
|
2018-02-01 |
2020-04-07 |
Homology Medicines, Inc. |
Adeno-associated virus compositions for PAH gene transfer and methods of use thereof
|
|
US20190256867A1
(en)
|
2018-02-01 |
2019-08-22 |
Homology Medicines, Inc. |
Adeno-associated virus compositions for restoring pah gene function and methods of use thereof
|
|
CA3090089A1
(en)
|
2018-02-06 |
2019-08-15 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Fluorescein-specific cars exhibiting optimal t cell function against fl-ple labelled tumors
|
|
CN112041437A
(zh)
|
2018-02-19 |
2020-12-04 |
同源药物公司 |
用于恢复f8基因功能的腺相关病毒组合物和其使用方法
|
|
TW202000229A
(zh)
|
2018-02-23 |
2020-01-01 |
美商安德賽特公司 |
Car t細胞療法之順序方法
|
|
WO2019169291A1
(en)
|
2018-03-02 |
2019-09-06 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Use of il-34 to treat retinal inflammation and neurodegeneration
|
|
CN112384626A
(zh)
*
|
2018-04-05 |
2021-02-19 |
夜星克有限公司 |
Aav组合物、制造方法和使用方法
|
|
US12163129B2
(en)
|
2018-06-08 |
2024-12-10 |
University Of Massachusetts |
Antisense oligonucleotides to restore dysferlin protein expression in dysferlinopathy patient cells
|
|
WO2019236949A1
(en)
|
2018-06-08 |
2019-12-12 |
Avexis Inc. |
Cell-based assay for measuring drug product potency
|
|
JP2021529001A
(ja)
|
2018-06-29 |
2021-10-28 |
ウーハン ニューロフス バイオテクノロジー リミテッド カンパニーＷｕｈａｎ Ｎｅｕｒｏｐｈｔｈ Ｂｉｏｔｅｃｈｎｏｌｏｇｙ Ｌｉｍｉｔｅｄ Ｃｏｍｐａｎｙ |
レーベル遺伝性視神経症を治療するための組成物及び方法
|
|
AU2019323434A1
(en)
|
2018-08-20 |
2021-02-25 |
Wuhan Neurophth Biotechnology Limited Company |
Compositions and methods for treating leber's hereditary optic neuropathy
|
|
EP4613367A1
(en)
|
2018-09-21 |
2025-09-10 |
Acuitas Therapeutics, Inc. |
Systems and methods for manufacturing lipid nanoparticles and liposomes
|
|
EP3886919A1
(en)
*
|
2018-11-30 |
2021-10-06 |
Novartis AG |
Aav viral vectors and uses thereof
|
|
PT3898981T
(pt)
|
2018-12-18 |
2023-12-28 |
Ultragenyx Pharmaceutical Inc |
Métodos e composições para tratar doenças de armazenamento de glicogénio
|
|
PL3906066T3
(pl)
|
2019-01-04 |
2024-09-02 |
Ultragenyx Pharmaceutical Inc. |
Konstrukty do terapii genowej do leczenia choroby wilsona
|
|
CA3125485A1
(en)
|
2019-01-11 |
2020-07-16 |
Acuitas Therapeutics, Inc. |
Lipids for lipid nanoparticle delivery of active agents
|
|
EP3911410A1
(en)
*
|
2019-01-18 |
2021-11-24 |
Voyager Therapeutics, Inc. |
Methods and systems for producing aav particles
|
|
US12173290B2
(en)
|
2019-06-28 |
2024-12-24 |
Crispr Therapeutics Ag |
Materials and methods for controlling gene editing
|
|
CN120137971A
(zh)
|
2019-07-25 |
2025-06-13 |
诺华股份有限公司 |
可调节的表达系统
|
|
WO2021062012A1
(en)
|
2019-09-25 |
2021-04-01 |
Emory University |
Use of klk10 and engineered derivatizations thereof
|
|
CN113025633B
(zh)
|
2019-12-09 |
2024-08-27 |
武汉纽福斯生物科技有限公司 |
编码人nadh脱氢酶亚单位1蛋白的核酸及其应用
|
|
WO2021124152A1
(en)
|
2019-12-19 |
2021-06-24 |
Pfizer Inc. |
Compositions and methods for nucleic acid transfection using cationic polymers and stabilizers
|
|
TW202140791A
(zh)
|
2020-01-13 |
2021-11-01 |
美商霍蒙拉奇醫藥公司 |
治療苯酮尿症之方法
|
|
JP7703543B2
(ja)
|
2020-01-17 |
2025-07-07 |
ザ ユナイテッド ステイツ オブ アメリカ アズ リプリゼンテッド バイ ザ セクレタリー、デパートメント オブ ヘルス アンド ヒューマン サービシーズ |
Ｃｒｘ常染色体優性網膜症の処置のための遺伝子治療
|
|
EP4100428A4
(en)
|
2020-02-04 |
2024-03-06 |
Seattle Children's Hospital (DBA Seattle Children's Research Institute) |
CHIMERIC ANTI-DINITROPHENOL ANTIGEN RECEPTORS
|
|
EP4103724A1
(en)
|
2020-02-14 |
2022-12-21 |
Ultragenyx Pharmaceutical Inc. |
Gene therapy for treating cdkl5 deficiency disorder
|
|
EP4114958A1
(en)
|
2020-02-21 |
2023-01-11 |
Akouos, Inc. |
Compositions and methods for treating non-age-associated hearing impairment in a human subject
|
|
TW202208632A
(zh)
|
2020-05-27 |
2022-03-01 |
美商同源醫藥公司 |
用於恢復ｐａｈ基因功能的腺相關病毒組成物及其使用方法
|
|
DK4182297T3
(da)
|
2020-07-16 |
2025-12-01 |
Acuitas Therapeutics Inc |
Kationiske lipider til brug i lipid-nanopartikler
|
|
WO2022038164A1
(en)
*
|
2020-08-18 |
2022-02-24 |
Bia Separations D.O.O. |
Multimodal metal affinity processing aav capsids
|
|
US20230383278A1
(en)
|
2020-09-18 |
2023-11-30 |
The United States Of America,As Represented By The Secretary,Department Of Health And Human Services |
Novel adeno-associated viral (aav) vectors to treat hereditary methylmalonic acidemia (mma) caused by methylmalonyl-coa mutase (mmut) deficiency
|
|
WO2022079082A1
(en)
|
2020-10-15 |
2022-04-21 |
F. Hoffmann-La Roche Ag |
Nucleic acid constructs for simultaneous gene activation
|
|
WO2022079083A1
(en)
|
2020-10-15 |
2022-04-21 |
F. Hoffmann-La Roche Ag |
Nucleic acid constructs for va rna transcription
|
|
WO2023042104A1
(en)
|
2021-09-16 |
2023-03-23 |
Novartis Ag |
Novel transcription factors
|
|
WO2023114943A2
(en)
|
2021-12-16 |
2023-06-22 |
Acuitas Therapeutics, Inc. |
Lipids for use in lipid nanoparticle formulations
|
|
WO2023196898A1
(en)
|
2022-04-07 |
2023-10-12 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Beta globin mimetic peptides and their use
|
|
EP4508241A1
(en)
|
2022-04-13 |
2025-02-19 |
F. Hoffmann-La Roche AG |
Method for determining aav genomes
|
|
CA3255627A1
(en)
|
2022-05-06 |
2023-11-09 |
Novartis Ag |
NEW VP2 FUSION POLYPEPTIDES OF RECOMBINANT AAV
|
|
WO2023227438A1
(en)
|
2022-05-23 |
2023-11-30 |
F. Hoffmann-La Roche Ag |
Raman-based method for the differentiation of aav particle serotype and aav particle loading status
|
|
WO2023232922A1
(en)
|
2022-06-03 |
2023-12-07 |
F. Hoffmann-La Roche Ag |
Method for producing recombinant aav particles
|
|
CA3261054A1
(en)
|
2022-07-14 |
2024-01-18 |
F. Hoffmann-La Roche Ag |
PROCESS FOR THE PRODUCTION OF RECOMBINANT ADENO-ASSOCIATED VIRUS PARTICLES
|
|
EP4587143A1
(en)
|
2022-09-12 |
2025-07-23 |
F. Hoffmann-La Roche AG |
Method for separating full and empty aav particles
|
|
KR20250141727A
(ko)
|
2023-02-07 |
2025-09-29 |
에프. 호프만-라 로슈 아게 |
항-aav 입자 항체 검출 방법
|
|
WO2024168358A1
(en)
|
2023-02-10 |
2024-08-15 |
Expression Therapeutics, Llc |
Lentiviral system
|
|
WO2024178113A1
(en)
|
2023-02-22 |
2024-08-29 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Recombinant adeno-associated virus vectors lacking an immunodominant t cell epitope and use thereof
|
|
EP4680243A1
(en)
|
2023-03-17 |
2026-01-21 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Methods for treatment of age-related macular degeneration
|
|
CN120835797A
(zh)
|
2023-03-21 |
2025-10-24 |
豪夫迈·罗氏有限公司 |
用于产生重组aav颗粒制备物的方法
|
|
WO2025090942A1
(en)
*
|
2023-10-26 |
2025-05-01 |
University Of Notre Dame Du Lac |
Gene therapy for treatment of neurometabolic disease
|
|
WO2025168663A1
(en)
|
2024-02-09 |
2025-08-14 |
F. Hoffmann-La Roche Ag |
Method for producing recombinant adeno-associated viral particles
|
|
WO2025252480A1
(en)
|
2024-06-07 |
2025-12-11 |
F. Hoffmann-La Roche Ag |
Method for purifying plasmid dna
|
|
US20260022401A1
(en)
|
2024-07-22 |
2026-01-22 |
Hoffmann-La Roche Inc. |
Novel AAV rep ORFs and Rep polypeptides
|
|
WO2026037757A1
(en)
|
2024-08-13 |
2026-02-19 |
F. Hoffmann-La Roche Ag |
Modified aav particles
|